

# WHAT'S HOT: IS IT TIME TO LOOK AT CHINA AGAIN?

Wisdomtree EU  
27 Aug 2021

2021's sharp declines in China-dominated Emerging Market equities have forced a considerable valuation re-rating - while stock exchanges in the U.S., Europe, Japan and other developed markets have largely witnessed static or rising valuations.

While the S&P 500 flirts with the 4,500 level, up from 3,756 at year-end, the MSCI China index has witnessed acute trouble, with an ugly downtrend persisting since February. You could be forgiven for not fully appreciating the damage, what with European giants such as Roche and LVMH continuing to make new highs, while American dynamos, including Facebook and Google-parent Alphabet, chug along in their multi-year ascent.

China's plunges happened across industries and business lines and at the "top of the house" too (Figure 1).

Figure 1 - MSCI China: Top 10 Components

| Company                        | 52 Week Low | 52 Week High | Last   | Decline from 52 Week High | Currency | % Weight in MSCI China Index |
|--------------------------------|-------------|--------------|--------|---------------------------|----------|------------------------------|
| Tencent                        | 422.00      | 775.50       | 471.80 | -39.2%                    | HKD      | 12.80%                       |
| Alibaba Group                  | 151.20      | 309.40       | 162.20 | -47.6%                    | HKD      | 11.64%                       |
| Meituan                        | 183.20      | 460.00       | 226.80 | -50.7%                    | HKD      | 3.83%                        |
| China Construction Bank        | 4.93        | 6.74         | 5.59   | -17.1%                    | HKD      | 2.52%                        |
| JD.com                         | 236.40      | 422.80       | 296.60 | -29.8%                    | HKD      | 2.41%                        |
| WuXi Biologics                 | 57.66       | 148.00       | 116.90 | -21.0%                    | HKD      | 1.91%                        |
| Ping An Insurance Co. of China | 61.55       | 103.60       | 62.00  | -40.2%                    | HKD      | 1.89%                        |
| NIO                            | 15.61       | 66.99        | 38.51  | -42.5%                    | USD      | 1.84%                        |
| Xiaomi                         | 19.40       | 35.90        | 24.45  | -31.9%                    | HKD      | 1.71%                        |
| Pinduoduo                      | 69.89       | 212.60       | 96.72  | -54.5%                    | USD      | 1.56%                        |

Source: WisdomTree, MSCI as of 8/25/2021. Historical

**Historical performance is not an indication of future performance and any investments may go down in value.**

## China's Declines Had No Shortage of Catalysts

Make no mistake, there have been several drivers. For one, the country's geopolitical risk premium has risen with each incursion into Taiwan's Air Defense Identification Zone. Additionally, the U.S. military's embarrassment in Kabul emboldens China's more hawkish generals, who may recalculate the odds of U.S. engagement in a Taiwanese military venture.

At the very least, the Afghanistan debacle gives China's social media-savvy "wolf warrior" diplomats a chance to stir the pot with antagonistic Twitter rhetoric. Meantime, notable billionaires Bernard Arnault (LVMH) and Jeff Bezos (Amazon) have nary a fear of false sequestration, yet that is exactly the fate that befell Alibaba's Jack Ma, who disappeared for several months after criticizing China's state-owned banks.

Additionally, questions abound about the profitability of China's largest company, Tencent, owing to Beijing's crackdowns on social media and gaming. That company's weight in many Chinese indexes is in the double digits.

To add onto the mess, the global supply chain is in such disarray that the Drewry World Container Index, the gauge of ocean freight costs, popped 351% over the last year. It remains anyone's guess when the Covid-inspired mess clears a path toward greater profitability for the country's export machine. Very grim, decidedly grim.

Nevertheless, it is all already "on the table." It's known, well-covered by the financial press. The question is if the sheer order of magnitude of the country's market declines this year offers up a buying opportunity. The answer may be yes.

## Conclusion

For example, the China-heavy WisdomTree Emerging Markets ex-State-Owned Enterprises Index, has estimated three-year sales growth of 13.8%, whereas the S&P 500's projection is 9.3%.

Despite headier growth prospects, the WisdomTree index trades for 21.1 times trailing earnings and 16.5 times forward earnings, a sharp discount to the 29.5 trailing and 22.2 multiples accorded the U.S. market. Meantime, the MSCI World index of developed equities is expected to have just 8.4% annual sales growth, yet its price to earnings (P/Es) are 26.8 on trailing earnings and 20 on forward earnings.

Similarly, the S&P 500 China is currently trading at 16.9 trailing and 14.9 forward earnings.

The potential valuation case for emerging equities looks considerably more opportune than it did six months ago.

## Source

Unless otherwise stated, all data from WisdomTree as of end of July 2021.

## Related blogs

- + [What's Hot: Q2 Earnings season – Europe in pole position](#)
- + [Emerging markets – in need of a jab](#)

View the online version of this article [here](#).

Important Information

**Marketing communications issued in the European Economic Area (“EEA”):** This document has been issued and approved by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

**Marketing communications issued in jurisdictions outside of the EEA:** This document has been issued and approved by WisdomTree UK Limited, which is authorised and regulated by the United Kingdom Financial Conduct Authority.

WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as “WisdomTree” (as applicable). Our Conflicts of Interest Policy and Inventory are available on request.

For professional clients only. The information contained in this document is for your general information only and is neither an offer for sale nor a solicitation of an offer to buy securities or shares. This document should not be used as the basis for any investment decision. Investments may go up or down in value and you may lose some or all of the amount invested. Past performance is not necessarily a guide to future performance. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice.

The application of regulations and tax laws can often lead to a number of different interpretations. Any views or opinions expressed in this communication represent the views of WisdomTree and should not be construed as regulatory, tax or legal advice. WisdomTree makes no warranty or representation as to the accuracy of any of the views or opinions expressed in this communication. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice.

This document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares or securities in the United States or any province or territory thereof. Neither this document nor any copy hereof should be taken, transmitted or distributed (directly or indirectly) into the United States.

Although WisdomTree endeavours to ensure the accuracy of the content in this document, WisdomTree does not warrant or guarantee its accuracy or correctness. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.